NANO-GBMNCT04881032
AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma
StatusActive, Not Recruiting
PhasePhase 1/2
SponsorCentre Jean Perrin
Primary completion (estimated)
At risk: Primary completion moved at least 1 year 1 month later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Sep 2025 to Nov 2026 Show 4 more changesShow less
- Eligibility criteria expanded, about 30 words
- Secondary endpoints: details revised at 1 of 8 entries
- Site details revised at 1 of 9 sites
- Publications: details revised at 1 of 1 entry
- Notable Eligibility criteria expanded, about 11 words
- Publications: details revised at 1 of 1 entry
- Notable Eligibility criteria revised
- Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 9 of 9 sites
- Notable Primary completion date: Sep 2024 to Sep 2025
- Study sites: 6 to 9
- Study completion date: Mar 2026 to Mar 2027
- Publications: details revised at 1 of 1 entry
- Minor Site details revised at 2 of 6 sitesv4
Show 2 earlier versionsHide 2 earlier versions
- Minor Primary completion date: May 2024 to Sep 2024
- Study completion date: Nov 2025 to Mar 2026
- Start date changed from estimate of Dec 2021 to Mar 7, 2022
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
- Start date: May 2021 to Dec 2021
- Primary completion date: Dec 2023 to May 2024
- Study completion date: May 2025 to Nov 2025
- Site details revised at 6 of 6 sites
- Collaborator revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
The recommended dose (phase I) of AGuIX in combination with TMZ and and radiotherapy during the radio-chemotherapy period
Timeframe: during 6 weeks after the first injection of AGuIX
6-month Progression Free Survival (PFS) rate (phase II)
Timeframe: 6 months from the start of treatment
Secondary (8)
Pharmacokinetic Cmax of AGuIX
Pharmacokinetic Tmax of AGuIX
Pharmacokinetic AUC of AGuIX
Pharmacokinetic t1/2 of AGuIX
distribution of AGuIX
Show 3 moreShow less
Overall Survival
Progression Free Survival (PFS)
Toxicity (CTCAE criteria)
Arms and interventions
AGuIX + chemoradiotherapy (radiotherapy + temozolomide)Experimental
addition of AGuIX nanoparticles to standard radiotherapy and concomitant treatment by temozolomide (TMZ) for patients of phase I and patients randomized in experimental arm of phase II
chemoradiotherapy (radiotherapy + temozolomide)Sham comparator
standard of care : chemoradiotherapy (radiotherapy + temozolomide) for patients randomized in control arm of phase II
Drugs: Polysiloxane Gd-Chelates based nanoparticles (AGuIX), Temozolomide
Radiation: radiotherapy
Sites
9 sites in 1 country